Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Core Viewpoint - Calidi Biotherapeutics, Inc. has successfully closed a registered direct offering and a concurrent private placement, raising approximately $3.9 million to support its clinical programs and working capital needs [4]. Group 1: Offering Details - The company issued and sold 3,325,000 shares of common stock and pre-funded warrants to purchase up to 2,728,000 shares [1]. - The combined offering price for each share of common stock and accompanying warrants was $0.65, with pre-funded warrants priced at $0.649 [2]. - The Series G warrants have an exercise price of $0.6954 per share and are exercisable six months from issuance, expiring seven and a half years after the initial exercise date [2]. Group 2: Use of Proceeds - Calidi intends to utilize the net proceeds from the offerings for working capital, general corporate purposes, and to advance its pre-clinical and clinical programs [4]. Group 3: Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted immunotherapies using proprietary technology to enhance the immune system's ability to fight cancer [8]. - The company employs novel stem cell-based platforms to deliver oncolytic viruses for various oncology indications, including high-grade gliomas and solid tumors [8].